Het Institute of Cancer Research in Londen is ‘very disappointed that NICE has not felt able to recommend use of abiraterone for men with prostate cancer who are yet to receive chemotherapy.’ Dit stelt ICR Deputy Chief Executive prof. Paul Workman BSc PhD DSc (Hon) FmedSci FSC FRSC op de website van het ICR.